Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Celecoxib

Celecoxib

Celebrex, Consensi, Elyxyb, Seglentis, Vyscoxa

NSAID • Selective COX-2 inhibitor

Premium
BleedingNephrotoxic

Half-life

11 hours

Protein Binding

Metabolized By

CYP2C9

External

Drugs.com

Mechanism of Action

Selectively inhibits COX-2, reducing inflammatory prostaglandins with less GI toxicity

Indications(5)

Metastatic Oral Cavity CarcinomaRecurrent Oral Cavity CarcinomaStage IVC Lip and Oral Cavity Cancer AJCC v8Osteoarthritis of the KneeDiffuse Large B-Cell Lymphoma (DLBCL)

Classification

Drug Class

NSAID

Subclass

Selective COX-2 inhibitor

Brand Names

CelebrexConsensiElyxybSeglentisVyscoxa

Key Properties

Half-life

11 hours

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Celecoxib Drug Profile | PharmaGraphX